Table 3 Relation between patient characteristics and Ki-67 score

From: Ki-67 in endometrial cancer: scoring optimization and prognostic relevance for window studies

Characteristic

Number of patients (%)

Median Ki-67 score % (interquartile range)

P-value

All

179

40 (24–52)

 

Age at diagnosis

  

0.022*

 Median (years)

68

  

 Interquartile range (years)

60–74

  

Body mass index (kg/m2)

  

0.663

 <25

22 (12)

44 (26–58)

 

 25–29.9

35 (20)

28 (17–47)

 

 ≥30

64 (36)

41 (26–51)

 

 Missing data

58 (32)

43 (28–55)

 

Grade

   

 1

39 (22)

23 (10–39)

<0.0001****

 2

36 (20)

41 (26–50)

 

 3

104 (58)

44 (30–55)

 

Stage

  

0.014**

 1

108 (60)

36 (22–50)

 

 2

22 (12)

37 (24–55)

 

 3

42 (24)

44 (29–56)

 

 4

6 (3)

54 (45–67)

 

Missing data

1 (1)

17 (17–17)

 

Histological type

  

0.246

 Endometrioid

116 (65)

37 (23–51)

 

 Non-endometrioida

63 (35)

44 (28–54)

 

Lymphovascular space invasion

  

0.138

 Absent

93 (52)

37 (22–50)

 

 Present

70 (39)

42 (25–55)

 

 Missing data

16 (9)

45 (31–53)

 

Depth of myometrial invasion

  

0.030*

 <50%

83 (46)

32 (20–50)

 

 ≥50%

92 (51)

43 (28–53)

 

 Missing data

4 (2)

42 (33–51)

 

Any adjuvant therapy

  

0.031*

 No

61 (34)

32 (22–49)

 

 Yesb

102 (57)

44 (27–55)

 

 Missing data

16 (9)

35 (26–45)

 
  1. Ki-67 expression positively correlated with age at the time of surgery, grade, and stage of endometrial cancer. Higher scores were seen in tumors with >50% myoinvasion compared with more superficially invasive cancers and women receiving adjuvant therapy. There was no association between Ki-67 and body mass index, histological type of endometrial cancer, and lymphovascular space invasion (P>0.05).
  2. aGrade 3 endometrioid tumors are classified within the endometrioid subtype. Non-endometrioid tumors include serous, clear cell, carcinosarcomas, mixed, and undifferentiated cancers.
  3. bAdjuvant treatment included external beam radiotherapy (44, 25%), vaginal brachytherapy (21, 12%) or both (25, 14%), and/or chemotherapy (39, 22%), which was single-agent carboplatin (2, 1%) or carboplatin/paclitaxel-based (29, 16%). Data on chemotherapy regime absent in 8 (5%) of cases. *p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001.
Back to article page